SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Can-Fite BioPharma Ltd.
Date: July 15, 2025 · CIK: 0001536196 · Accession: 0000000000-25-007441

Offering / Registration Process Regulatory Compliance Financial Reporting
View on Edgar

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
July 15, 2025
Author
Division of
Form
UPLOAD
Company
Can-Fite BioPharma Ltd.

Letter

Re: Can-Fite BioPharma Ltd. Draft Registration Statement of Form F-1 Submitted on July 9, 2025 CIK No. 0001536196 Dear Motti Farbstein:

July 15, 2025

Motti Farbstein Chief Executive Officer Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan 5257346 Israel

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Gary Emmanuel, Esq.

Show Raw Text 
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 15, 2025

Motti Farbstein
Chief Executive Officer
Can-Fite BioPharma Ltd.
26 Ben Gurion Street
Ramat Gan 5257346 Israel

 Re: Can-Fite BioPharma Ltd.
 Draft Registration Statement of Form F-1
 Submitted on July 9, 2025
 CIK No. 0001536196
Dear Motti Farbstein:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Chris Edwards at 202-551-6761 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Gary Emmanuel, Esq.
</TEXT>
</DOCUMENT>